What is ruxolitinib tablets (JAKAVI)?

Ruxolitinib (JAKAVI) is a drug produced by the Swiss pharmaceutical company Novartis and is used to treat certain types of blood and bone marrow-related diseases. Its main ingredient is "Ruxolitinib" (Ruxolitinib), which belongs to a class of drugs called JAK inhibitors. JAK (Januskinase) is an enzyme that plays an important role in the human immune response. By inhibiting JAK, ruxolitinib can reduce the inflammatory response caused by an overactive immune system.

Ruxolitinib tablets are most commonly used to treat diseases such as "myelofibrosis" (myelofibrosis) and "polycythemia vera" (polycythemia vera). Myelofibrosis is a disease that causes the bone marrow to fail to produce blood cells properly, often causing symptoms such as anemia and an enlarged spleen. Ruxolitinib modulates the symptoms of these diseases and helps improve patients' quality of life by acting on JAK1 and JAK2.

In addition, ruxolitinib is also used to treat certain types of immune-related diseases, especially some chronic diseases caused by overactivation of the immune system. It reduces unnecessary inflammation and tissue damage by regulating the immune response. The effect is usually significant, but it may also be accompanied by certain side effects, such as increased risk of infection, hematological changes, etc.

When using ruxolitinib, patients need regular blood tests and other monitoring to ensure that the drug is being used within a safe range. Doctors will usually adjust the dose based on the patient's specific condition and provide necessary guidance. Overall, ruxolitinib is an effective treatment, but it needs to be used under the guidance of a doctor to ensure maximum benefit and minimal side effects.